MASTER DAPT

The MASTER DAPT study shows short DAPT to be noninferior to standard therapy of at least two months in terms of net and major adverse clinical events.

Special Topic

New insight from MASTER DAPT

MASTER DAPT Complex PCI sub-analysis presented at EuroPCR 2022. You can download it here.

MASTER DAPT result

Click here to download a summary of trial primary endpoints.

MASTER DAPT Study Highlights

Investigator-initiated

global randomized study

4,579 patients,

140 hospital worldwide, 30 countries

All-comers trial in

HBR patients after PCI

Abbreviated vs prolonged

DAPT in patients treated with

the Utltimaster™and Ultimaster™ Tansei™

DAPT in patients
treated with the
Ultimaster™ and
Ultimaster™Tansei™

To receive more information about the clinical study or our product,

CLICK HERE

We will contact you after your request.

Study Design

MASTER DAPT Primary Endpoints

MASTER DAPT study had three primary endpoints

Net adverse clinical events (NACE) defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.

Major or clinically relevant non-major bleeding (MCB), defined as BARC 2, 3 or 5 bleeding.

Major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.

To receive more information about the clinical study or our product,

CLICK HERE

We will contact you after your request.

NACE

Diﬀerence in cumulative incidence,
0.23 percentage points (95% CI, 1.80 to 1.33)
P<0.001 for noninferiority

MACCE

Diﬀerence in cumulative incidence,
0.11 percentage points (95% CI, 1.29 to 1.51)
P=0.001 for noninferiority

Major or clinically relevant non-major bleeding

Diﬀerence in cumulative incidence,
-2.82 percentage points (95% CI, 4.40 to 1.24)
P<0.001 for superiority

Publications on MASTER DAPT

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. Marco Valgimigli, M.D., Ph.D et al. The New England Journal of Medicine, August 28, 2021, DOI: 10.1056/NEJMoa2108749

To receive more information about the clinical study or our product,

CLICK HERE

We will contact you after your request.

Reference

Special Topics

featured_ultimaster_features_europcr2022_master_dapt

New insight from MASTER DAPT

MASTER DAPT Complex PCI sub-analysis presented at EuroPCR 2022. You can download it here.

Download new insight

DOWNLOAD new Insight of distal radial @EuroPCR 2022 (1.07 MB)

featured_ultimaster_features_download_master_dapt_880x544.png

MASTER DAPT result

Click here to download a summary of MASTER DAPT trial primary endpoints.

Download Summary

DL Summary - MASTER DAPT OAC (196.63 KB)

ESC TV @ #ESC Congress 2021

Speaker - Dr. Marco
Interview about MASTR DAPT Trial

MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe.